Lentinan potentiates immunity and prolongs the survival time of some patients

Anticancer Research

Volumn 17, Issue 4 A, 1997, Pages 2751-2755

  Matsuoka, Hideo ^a   Seo, Yousuke ^a   Wakasugp, Hideyuki ^a   Saito, Takao ^a   Tomoda, Hirotsugu ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Cytokine; Helper inducer T cell; Killer T cell; Lentinan; Suppressor T cell

Indexed keywords

BETA1 INTEGRIN; CD11 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSTIMULATING AGENT; IMMUNOSUPPRESSIVE ACID PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LENTINAN; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNITY; IMMUNOPOTENTIATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE SUBPOPULATION; MALE; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYTOKINES; DINOPROSTONE; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; IMMUNOPHENOTYPING; LENTINAN; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0030809349     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Chihara G, Maeda Y, Hamuro J, Sasaki T, Fukuoka F: Inhibition of mouse sarcoma-180 by polysaccharide from Lentinuns edodes (Berk) sing. Nature 222: 687-688, 1969.
2. Hamuro J, Wagner H, Rollinghoff M: ß-1,3-glucans as probe for T-cell specific immune adjuvants. Enhanced in vitro generation of cytotoxic T-lymphocytes. Cell Immun 38: 328-325, 1978.
3. Hamuro J, Rollinghoff M, Wagner H: ß-1, 3-glucan mediated augmentation of alloreactive murine cytotoxic T-lymphocytes in vivo. Cancer Res 38: 3080-3085, 1978.
4. Herberman RB, Nunn-Hargrove ME: Augmentation of natural killer (NK) cell activity by lentinan. In: Aoki T, Urushizaki I, and Tsubura E, Manipulation of host defence mechanisms, Excerpta Medica, Amsterdam, p188-193, 1981.
5. Peter G, Karoly V, Imre B, Janos F. Kaneko Y: Effects of lentinan on Cytotoxic functions of human lymphocytes. Immunopharmac Immunotoxic 10: 157-163, 1988.
6. Ohkubo T, Fujitsuka H, Tanaka T, Ohnoma T, Tatematsu N, Oka N, Tokimatsu N: Synergistic antitumor effect of lentinan combined with cisplatin or rIL-2 against VX2 carcinoma in domestic rabbits. Biotherapy 5: 1916-1922, 1991.
7. Shimazaki I, Suga T, Izawa M, Akiyama Y: Effectiveness of combination therapy of lentinan andcisplatin. Biotherapy 7: 973-978, 1993.
8. Matsuo K, Takayama S, Oda S, Tohara K, Nakamura E, Otaki M: Acaseof recurrent gastric cancereffectively treated with endoscopic intratumoral injection of cisplatin and intravenous administration of lentinan. Biotherapy 5: 2023-2028 1991.
9. Taguchi T, Furue H, Kimura T, Kondo T, Hattori T, Itoh I, Ogawa N: End-point results of phase m study of lentinan. Jpn J Cancer Chemother 12: 366-378, 1985.
10. Taguchi T, Furue H, Majima H: Phase II study of lentinan. Jan J Cancer Chemother 3: 422-434, 1981.
11. Furue H, Itoh I, Kimura T, Kondo T, Hattori T, Ogawa N, Taguchi T: Phase m study on lentinan. Jpn J Cancer Chemother 8: 944-966, 1981.
12. Mihara H, Katoh Y, Yamamoto M, Ueshima S, Kobayashi H, Hasegawa T, Katoh Y, Oguri T, Sugawara Y: Lentinan induces precursors of LAK cells in patients with gastic cancer. Biotherapy 4: 117-122, 1990.
13. Takase K: Differentiation antigene related to functional subsets of human lymphocytes. Clin Immunol 19: 1-9, 1987.
14. Gambi D, Porrini AM, Giampietro A, Macor S: CD21+ (B2 antigen+) cell decrement and CD4+CD29+ (helper-inducer) cell increment suggest an activation of cell immune reactivity m multiple sclerosis. J Neuroimmunol 33: 97-102, 1991.
15. Takatsuki F, Miyasaka Y, Suzuki M, Kikuchi T, Hamuro J: Effects of lentinan on recovery of hematopoietic function in chemotherapeutic agent treated mice. Biotherapy 5: 688-692, 1991.
16. Koie H, Orita K, Hosokawa M, Fukushima M, Nishihira T: Report of the host factors investigation committee, society of cancer immuno-surgery. Biotherapy 5: 1561-1574, 1991.
17. Ueo H, Inoue H, Honda M, Uchida I, Nishimura M, Armaga S, Nakashima H, Akiyoshi T: Production of interleuken6 at operative wound sites in surgical patients. J Am Coll Surgeons 179: 326-332, 1994
18. Marsuoka H, Furusawa M. Tomoda H, Seo Y, Sugimachi K: Efficacy of indomethacin pretreatment with regional hyperthermia for treating upper abdominal malignancies. Int J Hyperthermia 11: 169-171, 1995.
19. Iketomi K: A study on the role of granulocytes in carcinoma-beanng hosts. J Jpn Soc Cancer Ther 25: 662-671, 1990.
20. Gazitt Y, He YJ, Keith S, Stelzer GT, Cohen RJ: Isolation and characterization of an early T-helper/ inducer cell line with a unique pattern of surface phenotype, constitutive cytokine secretion and myc oncogene expression. Leukemia 7: 2034-2044, 1993.